A time-indexed reference standard of adverse drug reactions

Scientific Data

Volumn 1, Issue , 2014, Pages

  Harpaz, Rave ^a   Odgers, David ^a   Gaskin, Greg ^a   DuMouchel, William ^b   Winnenburg, Rainer ^c   Bodenreider, Olivier ^c   Ripple, Anna ^c   Szarfman, Ana ^d   Sorbello, Alfred ^d   Horvitz, Eric ^e   White, Ryen W ^e   Shah, Nigam H ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Oracle Health Sciences   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^e MICROSOFT RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVERSE DRUG REACTION; DATA MINING; DRUG LABELING; DRUG SCREENING; DRUG SURVEILLANCE PROGRAM; FOOD AND DRUG ADMINISTRATION; HUMAN; MEDLINE; STANDARD; STANDARDS; TIME FACTOR; UNITED STATES;

ADVERSE DRUG REACTION REPORTING SYSTEMS; DATA MINING; DRUG EVALUATION; DRUG LABELING; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; MEDLINE; REFERENCE STANDARDS; TIME FACTORS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84940669952     PISSN: None     EISSN: 20524463     Source Type: Journal    
DOI: 10.1038/sdata.2014.43     Document Type: Article

References (36)

1. Lazarou, J., Pomeranz, B. H. & Corey, P. N. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 279, 1200-1205 (1998).
2. Classen, D. C., Pestotnik, S. L., Evans, R. S., Lloyd, J. F. & Burke, J. P. Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. JAMA 277, 301-306 (1997).
3. Ahmad, S. R. Adverse drug event monitoring at the Food and Drug Administration - Your report can make a difference. J. Gen. Intern. Med. 18, 57-60 (2003).
4. Harpaz, R. et al. Novel data-mining methodologies for adverse drug event discovery and analysis. Clin. Pharmacol. Ther. 91, 1010-1021 (2012).
5. Harpaz, R. et al. Performance of pharmacovigilance signal-detection algorithms for the FDA adverse event reporting system. Clin. Pharmacol. Ther. 93, 539-546 (2013).
6. Honig, P. K. Advancing the science of pharmacovigilance. Clin. Pharmacol. Ther. 93, 474-475 (2013).
7. Szarfman, A., Machado, S. G. & O'Neill, R. T. Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA's spontaneous reports database. Drug Saf. 25, 381-392 (2002).
8. Platt, R. et al. The New Sentinel Network - Improving the evidence of medical-product safety. N. Eng. J. Med. 361, 645-647 (2009).
9. Stang, P. E. et al. Advancing the science for active surveillance: rationale and design for the observational medical outcomes partnership. Ann. Intern. Med. 153, 600-606 (2010).
10. White, R. W., Harpaz, R., Shah, N. H., DuMouchel, W. & Horvitz, E. Toward enhanced pharmacovigilance using patientgenerated data on the internet. Clin. Pharmacol.Ther. 96, 239-246 (2014).
11. Coloma, P. M. et al. Combining electronic healthcare databases in Europe to allow for large-scale drug safety monitoring: the EUADR Project. Pharmacoepidemiol. Drug Saf. 20, 1-11 (2011).
12. LePendu, P. et al. Pharmacovigilance using clinical notes. Clin. Pharmacol. Ther. 93, 547-555 (2013).
13. Harpaz, R. et al. Combing signals from spontaneous reports and electronic health records for detection of adverse drug reactions. JAMIA 20, 413-419 (2013).
14. Shetty, K. D. & Dalal, S. R. Using information mining of the medical literature to improve drug safety. JAMIA 18, 668-674 (2011).
15. Avillach, P. et al. Design and validation of an automated method to detect known adverse drug reactions in MEDLINE: a contribution from the EU-ADR project. JAMIA 20, 446-452 (2013).
16. Pontes, H., Clement, M. & Rollason, V. Safety signal detection: the relevance of literature review. Drug Saf. 37, 471-479 (2014).
17. Leaman, R. et al. in Proceedings of the 2010 Workshop on Biomedical Natural Language Processing, 117-125 (2010).
18. Edwards, I. R. & Lindquist, M. Social media and networks in pharmacovigilance. Drug Saf. 34, 267-271 (2011).
19. White, R. W., Tatonetti, N. P., Shah, N. H., Altman, R. B. & Horvitz, E. Web-scale pharmacovigilance: listening to signals from the crowd. JAMIA 20, 404-408 (2013).
20. Vilar, S. et al. Facilitating adverse drug event detection in pharmacovigilance databases using molecular structure similarity: application to rhabdomyolysis. JAMIA 18(Suppl 1): i73-i80 (2011).
21. Chiang, A. P. & Butte, A. J. Data-driven methods to discover molecular determinants of serious adverse drug events. Clin. Pharmacol. Ther. 85, 259-268 (2009).
22. Ryan, P. B. et al. Defining a reference set to support methodological research in drug safety. Drug Saf. 36(Suppl 1), S33-S47 (2013).
23. Coloma, P. M. et al. A reference standard for evaluation of methods for drug safety signal detection using electronic healthcare record databases. Drug Saf. 36, 13-23 (2013).
24. Harpaz, R., DuMouchel, W., LePendu, P. & Shah, N. H. in Proceedings of the 19th ACM SIGKDD International Conference on Knowledge Discovery and Data Mining 13, 1339-1347 (2013).
25. Noren, G. N., Caster, O., Juhlin, K. & Lindquist, M. Zoo or Savannah? Choice of training ground for evidence-based pharmacovigilance. Drug Saf. 37, 655-659 (2014).
26. FDA's MedWatch. http://www.fda.gov/Safety/MedWatch/SafetyInformation/Safety-RelatedDrugLabelingChanges/default.htm.
27. Drugs@FDA. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/.
28. RxNorm. https://www.nlm.nih.gov/research/umls/rxnorm/.
29. MedDRA. http://www.meddra.org/.
30. UMLS. http://www.nlm.nih.gov/research/umls/.
31. Guidance for Industry. Warnings and Precautions, Contraindications, and Boxed Warning Sections of Labeling for Human Prescription Drug and Biological Products-Content and Format. http://www.fda.gov/downloads/Drugs/Guidances/ucm075096.pdf.
32. Anatomical Therapeutic Chemical Classification System. http://www.whocc.no/atc.
33. DuMouchel, W. & Pregibon, D. in Proceedings of the 7th ACM SIGKDD International Conference on Knowledge Discovery and Data Mining 01, 67-76 (2001).
34. MEDLINE. http://www.nlm.nih.gov/pubs/factsheets/medline.html.
35. Boyce, R. et al. Bridging Islands of Information to establish an integrated knowledge base of drugs and health outcomes of interest. Drug Saf. 37, 1-11 (2014).
36. IMI Protect. http://www.imi-protect.eu/adverseDrugReactions.shtml.